FOLH1 and prostate cancer: <i>In vivo</i>, scintigraphy imaging visualized the accumulation of [<sup>161</sup>Tb]-PSMA-617 in the prostate, kidneys, and bladder.<h4>Conclusions</h4>The results suggest that [<sup>161</sup>Tb]-PSMA-617 can be an effective radiolabeled agent for the treatment of PSMA positive foci in prostate cancer.